Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors

Sodium–glucose cotransport 2 inhibitors (SGLT2i) lower plasma glucose but stimulate endogenous glucose production (EGP). The current study examined the effect of dapagliflozin on EGP while clamping plasma glucose, insulin, and glucagon concentrations at their fasting level. Thirty-eight patients with type 2 diabetes received an 8-h measurement of EGP ([3-3H]-glucose) on three occasions. After a 3-h tracer equilibration, subjects received 1) dapagliflozin 10 mg (n = 26) or placebo (n = 12); 2) repeat EGP measurement with the plasma glucose concentration clamped at the fasting level; and 3) repeat EGP measurement with inhibition of insulin and glucagon secretion with somatostatin infusion and replacement of basal plasma insulin and glucagon concentrations. In study 1, the change in EGP (baseline to last hour of EGP measurement) in subjects receiving dapagliflozin was 22% greater (+0.66 ± 0.11 mg/kg/min, P < 0.05) than in subjects receiving placebo, and it was associated with a significant increase in plasma glucagon and a decrease in the plasma insulin concentration compared with placebo. Under glucose clamp conditions (study 2), the change in plasma insulin and glucagon concentrations was comparable in subjects receiving dapagliflozin and placebo, yet the difference in EGP between dapagliflozin and placebo persisted (+0.71 ± 0.13 mg/kg/min, P < 0.01). Under pancreatic clamp conditions (study 3), dapagliflozin produced an initial large decrease in EGP (8% below placebo), followed by a progressive increase in EGP that was 10.6% greater than placebo during the last hour. Collectively, these results indicate that 1) the changes in plasma insulin and glucagon concentration after SGLT2i administration are secondary to the decrease in plasma glucose concentration, and 2) the dapagliflozin-induced increase in EGP cannot be explained by the increase in plasma glucagon or decrease in plasma insulin or glucose concentrations.

[1]  R. DeFronzo,et al.  Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes , 2017, Diabetes.

[2]  J. Holst,et al.  No direct effect of SGLT2 activity on glucagon secretion , 2019, Diabetologia.

[3]  R. DeFronzo,et al.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition , 2017, Nature Reviews Nephrology.

[4]  M. Halliwell,et al.  Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. , 1991, Clinical science.

[5]  R. DeFronzo,et al.  Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes , 2020, Diabetes Care.

[6]  T. Pieber,et al.  Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes , 2016, Diabetes.

[7]  Maria J. Pereira,et al.  Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes , 2018, The Journal of clinical endocrinology and metabolism.

[8]  M. Zinner,et al.  Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog. , 1985, Gastroenterology.

[9]  F. Pattou,et al.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.

[10]  G. Shulman,et al.  Regulation of hepatic glucose metabolism in health and disease , 2017, Nature Reviews Endocrinology.

[11]  S. R. Wagle,et al.  Studies on the mechanism of action of somatostatin on renal gluconeogenesis: evidence for the involvement of alpha 1-adrenergic stimuli. , 1982, Archives of biochemistry and biophysics.

[12]  A. Cherrington,et al.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.

[13]  R. DeFronzo,et al.  Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. , 2015, American journal of physiology. Renal physiology.

[14]  M. Zinner,et al.  The effect of somatostatin on central hemodynamics, renal blood flow, and renal function in dogs. , 1985, Surgery.

[15]  R. DeFronzo,et al.  Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy , 2018, Diabetes.

[16]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[17]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.